Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Glyset Articles

Miglitol effective in combination with metformin

11 October 1999

Quality, not quantity, sums up New Chemical Entity launches in 1998

7 January 1999

P&U Gains Miglitol Rights

10 September 1998

Miglitol Debuts In Germany

18 June 1998

Bayer "Unperturbed" By Wave Of Mergers

18 March 1998

Product License News In Brief

20 November 1997

Bayer Health Care Sales Fueled By Older Products

25 March 1997

Bayer Pharma Starts New Product Cycle

20 March 1997

Bayer's Miglitol Gains Approval In USA

20 January 1997

First Approval for Miglitol In Holland

11 November 1996

Morgan Stanley, the investment broker, has published a report

8 July 1996

Bayer Details Near-Term Product Expectations

1 April 1996

Revolution In Diabetes Type II Treatment Forecast

23 October 1995

Bayer's Acarbose Approved In USA

18 September 1995

Bayer's First Pipeline Presentation: Part 1

19 June 1995

Bayer Adapting Pharma Business

12 December 1994

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS